Nicholas Hornstein, Assistant Professor at Northwell Health, shared a post on LinkedIn:
“NEOSUMMIT-01, now presented
Randomized Ph II perioperative oxaliplatin-based doublet (CAPEOX or SOX) ± PD-1 inhibitor toripalimab in cT3–4N+ GC/GEJC.
For context: perioperative chemotherapy alone has produced only modest gains for decades, with relapse (especially peritoneal) remaining the dominant failure pattern.
NEOSUMMIT-01 delivers something we have not seen before
- 3-year EFS 74.7% vs 56.2%, HR 0.51, P=0.044
- 3-year OS 81.3% vs 72.2%, HR 0.45, P=0.036
- Metastasis/relapse nearly cut in half: 18.5% vs 38.9%, P=0.019
mEFS not reached with perioperative chemoIO vs 38.2 months with chemo alone
Benefits held up in per-protocol analyses and after excluding dMMR patients.
The dramatic reduction in peritoneal relapse is the standout.
CAVEAT: China only study. Unclear if results will translate to a global population.
These are fantastic results and set a high bar for perioperative chemoIO in locally advanced GC/GEJC.”
More posts featuring Nicholas Hornstein.
